Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The role of antiplatelet therapy in primary prevention. A review

Research output: Contribution to journalReviewResearchpeer-review

  1. Chronic Inflammatory Diseases and Atherosclerotic Cardiovascular Disease: Innocent Bystanders or Partners in Crime?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Management of antiepileptic treatment after epilepsy surgery - practices and problems

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Trimethylamine N-oxide (TMAO) as a new potential therapeutic target for insulin resistance and cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hyperpolarized (13)C MR Angiography

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Old, New and Hidden Causes of Perioperative Hypersensitivity

    Research output: Contribution to journalReviewResearchpeer-review

  1. Quality of life and the associated risk of all-cause mortality in nonischemic heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Ischaemic heart disease, infection, and treatment of infection

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The efficacy of antiplatelet therapy for the secondary prevention of cardiovascular disease after an ischemic event is well established. However, the role for antiplatelet therapy for the primary prevention of cardiovascular disease is more complex because of the interplay of efficacy vs safety in individuals without established cardiovascular disease who have a relatively low, but linear trajectory of cardiovascular risk. Several large randomized trials have investigated the efficacy and safety of antiplatelet therapy (primarily aspirin) for patients without established cardiovascular disease. The pharmacological profile of the most commonly used primary prevention antiplatelet agent, aspirin, has been delineated by randomized clinical trials and showcased in practice guidelines for reducing cardiovascular risk. For this indication, aspirin has been consistently shown to reduce the risk of non-fatal myocardial infarction with little impact on cardiovascular death, but with a consistent increased risk of bleeding. These divergent results have contributed to differences in the recommendations from international practice guidelines and highlight controversy at the forefront of considerations for anti-platelet therapy for primary prevention. However, further studies in specific sub-groups of patients without established cardiovascular disease such as those with Diabetes Mellitus, chronic kidney disease, or the elderly may clarify which patient groups will benefit the most from aspirin treatment for the primary prevention of a cardiovascular event.

Original languageEnglish
JournalCurrent Pharmaceutical Design
Volume23
Issue number9
Pages (from-to)1294-1306
ISSN1381-6128
DOIs
Publication statusPublished - 2017

ID: 49803637